METASTATIK SUT BEZI SARATONINING KECHISHIDA INDIKATOR SIFATIDA LIMFOSITLAR PROFILI
##article.subject##:
limfositlar profili, metastatik saraton, o'sma progressiyasi, immunitet holati##article.abstract##
Tadqiqot maqsadi: gepatogen metastazlari bilan kechayotgan ko‘krak bezi saratoni bo‘lgan 127 bemorda limfotsit subpopulatsiyalarining o‘zgarishini va ularning prognoz potentsialini baholash[1].
Metod: retrospektiv-prospektiv dizayn. 2016–2022 yillarda Samarqand onkologiya markazida davolangan bemorlar. 3067 gemogramma, 1116 biokimyoviy va 1247 koagulologik tahlil natijalari tahlil qilindi. Limfotsitlarning uch xil dinamika turi — tushuvchan, stabilli va to‘lqinli — aniqlangan[1].
Natijalar: Tushuvchan tip (41 nafar, 32,3%): limfotsitlar 35,0% dan 30,5% gacha kamaydi (Δ=4,5%, p<0,05, R²>0,85), bu immunosupressiya va limfopeniyani ko‘rsatadi. Stabilli tip (35 nafar, 27,6%): 33,0–34,5% oralig‘ida ozgina o‘zgarishlar, immungomeostaz saqlanganini bildiradi. To‘lqinli tip (51 nafar, 40,2%): 29,0–34,5% oralig‘ida 5,5% amplituda bilan tsiklik o‘zgarishlar, kimyoterapiyaning immun tiklanishiga moslashuvchan javobi.
Xulosa: stabilli dinamika standart ESMO/NCCN protokollari bo‘yicha davolashni yaxshi ko‘taradi, to‘lqinli tur fazali immun tiklanishni ko‘rsatadi, tushuvchan tur esa erta immunotsiklik terapiyasini talab etadi.
Библиографические ссылки
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
Xie J, Xu Z. A population-based study on liver metastases in women with newly diagnosed breast cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(2):283-292.
Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018;29(8):1634-1657.
Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717-734.
Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther. 2018;11:955-965.
Miyagawa Y, Araki K, Bun A, et al. Significant association between low baseline neutrophil-to-lymphocyte ratio and improved progression-free survival of patients with locally advanced or metastatic breast cancer treated with eribulin but not with nab-paclitaxel. Clin Breast Cancer. 2018;18(5):400-409.
Zakirova Nargiza Negmatovna , Osmanova Elnara Zodievna , Rahimov Nodir Makhammatkulovich , Ulmasov Firdavs Gayratovich . P16/KI67 PROGNOSTIC FACTORS IN DETECTION OF CERVICAL CANCER IN WOMEN WITH HIGH RISK HPV. Journal of Biomedicine and Practice. 2022, vol. 7, issue 5, pp. 217-226
Yorov , L. Sh., Juraev , M. D., Rakhimov, N. M. , Shakhanova , Sh. Sh. (2022). Assessment of the immune status in patients with breast cancer with determination of the effectiveness of neoadjuvant polychemotherapy . Journal of Biomedicine and Practice , 7 (5).
Shakhanova Shakhnoza , Rakhimov Nodir , Zaripova Parvina . Breast tumors in adolescent girls // Journal of Biomedicine and Practice. 2022, vol . 7, issue 3, pp.266-273
Lutfillo Yorov , Mirjalol Djuraev , Nodir Raximov , Shakhnoza Shakhanova . Evaluation
of the state of the immune status in patients with breast cancer with the determination of the
effectiveness of neoadjuvant polychemotherapy. Journal of Biomedicine and Practice. 2022, vol. 7, issue 5, pp.211-216
Гузаль, А., Тилляшайхов, М., Джанклич, С., Ососков-старший, А. и Хаджаев, А. (2025). Эпидемиология рака молочной железы и проблемы скрининга.
Тилляшайхов М. Н., Каххаров А. Ж., Юлдашходжаева Н. Б. ДИАГНОСТИЧЕСКИЕ ВОЗМОЖНОСТИ МИКРООКРУЖЕНИЯ ОПУХОЛИ ПРИ РАКЕ МОЛОЧНОЙ ЖЕЛЕЗЫ //Лучшие интеллектуальные исследования. – 2025. – Т. 41. – №. 2. – С. 18-26.
Izrailbekova, K., Kamishov, S., Saydullaev, S., Niyozova, S. K., Tillyashaykhov, M., Olimjonova, G., & Sobitov, A. (2024). The efficacy of PARP inhibitors in the treatment of patients with synchronous breast cancer.
